Breaking Finance News

Prima BioMed Ltd (ADR) (NASDAQ:PBMD) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Displaying a price of $0.89, Prima BioMed Ltd (ADR) (NASDAQ:PBMD) traded 1.23% lower on the day. The last stock price is down 6.58% relative to the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time. PBMD has registered a 50-day average of $0.87 and 200-day average of $0.95. Trade volume was was down over the average, with 87,576 shares of PBMD changing hands under the typical 149,136 shares.

Zacks Investment Research has downgraded Prima BioMed Ltd (ADR)(NASDAQ:PBMD) to Sell in a report released 9/20/2016.

See Chart Below:

Prima BioMed Ltd (ADR) (NASDAQ:PBMD)

A total of 4 brokers have released a ratings update on the stock. One analyst rate the company a strong buy, two firms rate the stock a buy, 0 firms rate the company a hold, 0 rate the stock to underperform, and lastly 0 brokeragesrate the company as sell with an average target of $6.03

Prima BioMed Ltd (ADR) has a 52 week low of $0.72 and a one-year high of $1.54. The company’s market capitalization is presently $0.0.

More About Prima BioMed Ltd (ADR) (NASDAQ:PBMD)

Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, and which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.